Magbind blood dna kit

Genomic DNA was extracted from patient peripheral blood (1–2 ml) samples using a Magbind Blood DNA Kit (CW Biotech, Beijing, China) according to the manufacturer’s instructions and was stored at − 20 °C. WES and TRS were performed as previously described [9 (link), 13 ]. In brief, whole exomes were captured using SeqCap EZ Exome (44 M) arrays (Roche, Basel, Switzerland). The targeted region was captured using a SeqCap Target Enrichment Kit (Roche) and sequenced using an Illumina HiSeq 2500 System (Illumina, San Diego, CA, USA) at BGI-Shenzhen (BGI, Shenzhen, China).

Peripheral venous blood samples were collected from each participant. Genomic DNA was extracted from peripheral blood leukocytes on a Tecan Freedom EVO platform (Tecan, Switzerland) using the Mag-Bind Blood DNA Kit (CWBIO, China). Single nucleotide polymorphisms (SNPs) genotyping work was performed using a custom-by-design 48-Plex SNPscan^TM Kit (Cat#:G0104; Genesky Biotechnologies Inc., Shanghai, China). SNPs were selected from their consistent associations with impaired insulin synthesis, secretion, action, or other T2D-related traits in genome-wide association studies and candidate gene studies, especially in Chinese or Asian, and had to meet the following criteria: fitting Hardy-Weinberg equilibrium, genotyping success rates exceed 95%, and the genotyping concordance of replicated quality-control samples exceed 95%. On these basics, 25 SNP were incorporated in our study [27 (link)–41 (link)]. The details of these SNPs are shown in Supplementary Table 2.

A total of 867 individuals not affected by ASD were recruited for validation of the variant frequency. The Magbind Blood DNA Kit (CW Biotech, Beijing, China) was used to extract the genomic DNA. CTTNBP2 p.M115T (c.344T > C) was further confirmed using the MassARRAY iPLEX platform (Agena Bioscience, San Diego, CA, USA), in accordance with the manufacturer’s manual [45 (link)].